A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn’s Disease
Inflammatory Bowel Diseases · 2023
DOI: 10.1093/ibd/izac117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Ariela K Holmer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, NYU Langone Health, New York, NY, USA. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, San Diego Digestive Diseases Research Center.
Abstract (Originalsprache)
Background
The Endoscopic Healing Index (EHI) is a serum biomarker panel that can predict endoscopic inflammation in Crohn’s disease (CD).
Methods
Paired serum samples with endoscopies from adult patients participating in a prospective biobank (June 2014 to December 2018) were analyzed post hoc. Diagnostic performance for EHI was assessed against the individual parameters of the Simple Endoscopic Score for CD using previously identified cutoffs. Confounders for EHI performance were identified using logistic regression.
Results
A total of 205 CD patients were included (50% male, median age 37 years). An EHI of 20 points was sensitive for ruling out any ulcers (85%; 95% confidence interval [CI], 77%-91%) and large (5-20 mm) or very large (>20 mm) ulcers (93%; 95% CI, 84%-97%). An EHI of 50 points was specific for ruling in any ulcers (86%; 95% CI, 76%-92%) and large or very large ulcers (87%; 95% CI, 79%-92%). After accounting for total extent of inflamed mucosa, strictures, and disease location, each 20-point increase in EHI was associated with a 1.7-fold increased probability for the presence of large or very large ulcers (adjusted odds ratio, 1.7; 95% CI, 1.1-2.6).
Conclusions
The EHI was independently associated with ulcer size and accurately identified large or very large ulcers. A cutoff of 50 points can reliably rule in mucosal ulcers and allow for treatment adjustment. A cutoff of 20 points can reliably rule out mucosal ulcers and signal completion of treatment adjustment algorithms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, NYU Langone Health, New York, NY, USA.
- Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
- Division of Biomedical Informatics, University of California San Diego, La Jolla, CA, USA.
- Division of Gastroenterology, Northwestern University, Chicago, IL, USA.
ORCID-Profile: Parambir S Dulai
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- San Diego Digestive Diseases Research Center
- National Institutes of Health
Zitieren
APA
Holmer, A. K., Boland, B. S., Singh, S., Neill, J., Le, H., Miralles, A., Collins, A. E., Sandborn, W. J., & Dulai, P. S. (2023). A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn’s Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac117
Vancouver
Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, et al. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn’s Disease. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac117
BibTeX
@article{Holmer2023,
author = {Holmer, Ariela K and Boland, Brigid S and Singh, Siddharth and Neill, Jennifer and Le, Helen and Miralles, Ara and Collins, Angelina E and Sandborn, William J and Dulai, Parambir S},
title = {A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn’s Disease},
journal = {Inflammatory Bowel Diseases},
year = {2023},
doi = {10.1093/ibd/izac117}
}
EUVIMED